# Ascending Multiple-Dose Study of Brivanib Alaninate in Combination With Chemotherapeutic Agents in Subjects With Advanced Cancers

> **NCT00798252** · PHASE1 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 111 (actual)

## Conditions studied

- Advanced Cancer

## Interventions

- **DRUG:** Capecitabine
- **DRUG:** Doxorubicin
- **DRUG:** Ixabepilone
- **DRUG:** Docetaxel
- **DRUG:** Paclitaxel
- **DRUG:** Brivanib alaninate

## Key facts

- **NCT ID:** NCT00798252
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-03
- **Primary completion:** 2015-05
- **Final completion:** 2015-05
- **Target enrollment:** 111 (ACTUAL)
- **Last updated:** 2015-07-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00798252

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00798252, "Ascending Multiple-Dose Study of Brivanib Alaninate in Combination With Chemotherapeutic Agents in Subjects With Advanced Cancers". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00798252. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*